Zevra Therapeutics (ZVRA) investor relations material

Executive summary

• Achieved strong Q1 2026 performance with net income of $37.9M, reversing a prior-year loss, driven by a $43.3M gain from the Commave Settlement Agreement, higher product revenues, and advancing the rare disease portfolio.

• Net revenue for Q1 2026 reached $36.2M, up 78% year-over-year, primarily from MIPLYFFA and expanded access programs.

• Completed $50M sale of the SDX portfolio, resolved litigation, and prepaid $63.1M in term loans, resulting in a debt-free balance sheet.

• Maintained strong liquidity with $236.8M in cash, cash equivalents, and investments as of March 31, 2026.

• Relocated headquarters to Boston and strengthened leadership team.

Financial highlights

• Q1 2026 net revenue was $36.2M, up from $20.4M in Q1 2025, with MIPLYFFA contributing $24.6M, OLPRUVA $0.3M, Global EAP $10.2M, and royalties $1.1M.

• Net income was $37.9M ($0.62 basic, $0.60 diluted EPS), compared to a net loss of $3.1M in Q1 2025.

• Adjusted net income (excluding one-time items) was $11.5M, or $0.18 per diluted share.

• Operating expenses rose to $25.2M (R&D: $4.4M, SG&A: $20.8M), with cost of product revenue at $1.9M.

• Cash flow from operations was $6.1M, a turnaround from negative $8.2M in Q1 2025.

Outlook and guidance

• Positioned for long-term growth with strong balance sheet and no debt; current resources sufficient to fund operations for at least the next year.

• Focused on expanding MIPLYFFA access globally, accelerating celiprolol development, and advancing regulatory milestones for arimoclomol.

• Confident in reaching more NPC patients and expanding total addressable market.

• Management expects continued investment in commercialization and R&D, with expenses expected to fluctuate as pipeline and commercial activities progress.